We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Rapid Diagnostic Tests (RDTs) for Malaria in Kampala, Uganda

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00327964
Recruitment Status : Completed
First Posted : May 19, 2006
Last Update Posted : October 2, 2008
Information provided by:

Study Description
Brief Summary:
Malaria remains a disease that causes much death and sickness, especially in sub-Saharan Africa. An accurate, simple, and inexpensive method of diagnosing malaria is urgently needed. The purpose of this study is to evaluate a different diagnostic method compared to those most frequently used. The study may also identify the factors causing false positive and false negative results using the alternative method. Participants will be 600 Ugandan children aged 1-10 years who are enrolled in protocol 04-068. Those who develop a fever over the 12 month duration of the study will be tested for malaria by both the standard and the new methods. These tests will require a few drops of blood to be collected by finger prick. Subjects will be treated on the basis of standard diagnostic testing (i.e. expert microscopy).

Condition or disease
Febrile Illness Malaria

Detailed Description:
Malaria remains one of the most devastating infectious diseases, causing high morbidity and mortality especially in sub-Saharan Africa. The need for an accurate, simple, and inexpensive method to diagnose malaria has become increasingly urgent. Rapid diagnostic tests (RDTs), based on detection of Plasmodium antigens, may represent a more practical diagnostic tool than traditional light microscopy. This longitudinal study's objectives are (1) to evaluate the clinical performance (sensitivity, specificity, positive and negative predictive values) of RDTs, as compared with presumptive diagnosis and microscopy, for the diagnosis of malaria in children in Kampala, Uganda, and (2) to identify host and test factors that lead to false positive and false negative RDT results by comparison with polymerase chain reaction (PCR) analysis. Study subjects in this RDT study will have already been enrolled in a larger on-going longitudinal study of antimalarial drug efficacy, tolerability, and safety that began at the Kampala study site in late 2004. In the RDT study, over a one-year period, study participants' blood samples will be evaluated with the current gold standard for malaria diagnosis (microscopy) as well as two types of RDT whenever they present with a new fever episode (the first fever after study enrollment, or a fever that occurs more than 14 days after the patient's most recently diagnosed episode of malaria). As part of the on-going longitudinal drug efficacy trial, probability sampling was used to select a random sample of 600 children, who will be followed for three years for all their health-care needs. The RDT study will involve evaluation of the cohort over 12 months, beginning in approximately the third quarter of 2005. This protocol is a substudy of 04-068.

Study Design

Study Type : Observational
Actual Enrollment : 600 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Utility of Rapid Diagnostic Tests (RDTs) for Malaria in Kampala, Uganda
Study Start Date : October 2005
Primary Completion Date : May 2006
Study Completion Date : May 2006

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Malaria
U.S. FDA Resources

Groups and Cohorts

study population
601 children enrolled in an on-going longitudinal antimalarial treatment efficacy trial in Kampala, Uganda.

Outcome Measures

Primary Outcome Measures :
  1. RDT accuracy

Biospecimen Retention:   Samples With DNA
Dried blood spots on filter paper

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   1 Year to 11 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
601 children enrolled in a longitudinal antimalarial treatment efficacy trial in Kampala, Uganda.

Inclusion Criteria: Member of the cohort participating in clinical trial of antimalarial drug efficacy in Kampala, which was enrolled based on criteria including the following characteristics:

  1. Ages 1-10 (at time of original enrollment)
  2. Parents' or guardians' agreement to bring the child to the study clinic for any fevers or other illnesses
  3. Agreement to avoid medications administered outside the study
  4. Intention to remain in Kampala for the full study period
  5. Native Ugandan

Exclusion Criteria:

  1. Presence of any known serious chronic disease (e.g. AIDS, sickle cell disease, malignancy)
  2. Serious side effects to study medications used in cohort clinical trial of antimalarial drug efficacy
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00327964

Mulago Hospital
Kampala, Uganda
Sponsors and Collaborators
University of California, San Francisco
National Institute of Allergy and Infectious Diseases (NIAID)
Principal Investigator: Heidi Hopkins, MD University of California, San Francisco
More Information

Additional Information:
Responsible Party: Heidi Hopkins, MD, University of California, San Francisco
ClinicalTrials.gov Identifier: NCT00327964     History of Changes
Other Study ID Numbers: NIH/DMID 05-0110
First Posted: May 19, 2006    Key Record Dates
Last Update Posted: October 2, 2008
Last Verified: October 2008

Keywords provided by University of California, San Francisco:
rapid diagnostic tests

Additional relevant MeSH terms:
Protozoan Infections
Parasitic Diseases